FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894817450> ?p ?o ?g. }

• W2894817450 endingPage "14" @default.
• W2894817450 startingPage "1" @default.
• W2894817450 abstract "Background/Aims: Urothelial cancer (UC) as a chemotherapy-sensitive tumor, has achieved remarkable progresses in therapeutic paradigm, particularly in the advanced/metastatic stages. However, both clinicians and patients are confused when it comes to choosing the optimal chemotherapy. Hence, this article was aimed to conduct a comprehensive comparison of different chemotherapy regimens for advanced or metastatic UC in terms of survival benefits or adverse events. Methods: The online databases PubMed, EMBASE and Web of Science were searched systematically and comprehensively for randomized controlled trials (RCTs) up to September 15, 2017. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% credible interval (CrI) were calculated by Markov chain Monte Carlo methods. The effectiveness and safety of included regimens were conducted to provide a hierarchy by means of rank probabilities with the help of “R-3.4.0” software and the “gemtc-0.8.2” package. The surface under the cumulative ranking curve (SUCRA) was also incorporated in our analysis for ranking the corresponding chemotherapy regimens. Results: Ten different chemotherapy regimens involved in this article were predominantly of trials in a first-line setting, and eight clinical outcomes were ultimately analyzed in this study. In terms of Overall response rate (ORR), Overall survival (OS) or Progression-free survival (PFS)/Time to progression (TTP), the rank probabilities and SUCRA indicated that Paclitaxel/cisplatin/gemcitabine (PCG) was superior to gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC), the traditional first-line treatment for advanced/metastatic UC. In the case of ORR or PFS/TTP, GC+sorafenib also displayed its superiority in comparison with GC or MVAC. Despite their survival benefits, PCG or GC+sorafenib presented a relatively higher incidence of adverse events. Conclusion: Our results revealed that by adding a paclitaxel or sorafenib into the first-line GC, it could yield a better survival benefit, but also worsen adverse events for advanced/ metastatic UC. Clinically, physicians should weigh the merits of these approaches to maximize the survival benefits of eligible patients." @default.
• W2894817450 created "2018-10-12" @default.
• W2894817450 creator A5014374711 @default.
• W2894817450 creator A5014687439 @default.
• W2894817450 creator A5025814758 @default.
• W2894817450 creator A5042133353 @default.
• W2894817450 creator A5062233182 @default.
• W2894817450 creator A5062553515 @default.
• W2894817450 creator A5063253432 @default.
• W2894817450 creator A5075136340 @default.
• W2894817450 creator A5085338227 @default.
• W2894817450 creator A5087611125 @default.
• W2894817450 creator A5087798680 @default.
• W2894817450 date "2018-01-01" @default.
• W2894817450 modified "2023-10-16" @default.
• W2894817450 title "Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials" @default.
• W2894817450 cites W1525365346 @default.
• W2894817450 cites W1586024750 @default.
• W2894817450 cites W1588429113 @default.
• W2894817450 cites W1833688292 @default.
• W2894817450 cites W1893740135 @default.
• W2894817450 cites W1967385770 @default.
• W2894817450 cites W1968487988 @default.
• W2894817450 cites W1976411264 @default.
• W2894817450 cites W1986382801 @default.
• W2894817450 cites W1994334230 @default.
• W2894817450 cites W2101562875 @default.
• W2894817450 cites W2103257412 @default.
• W2894817450 cites W2103818040 @default.
• W2894817450 cites W2105669432 @default.
• W2894817450 cites W2107328434 @default.
• W2894817450 cites W2113144077 @default.
• W2894817450 cites W2114822580 @default.
• W2894817450 cites W2121607722 @default.
• W2894817450 cites W2124010429 @default.
• W2894817450 cites W2125435699 @default.
• W2894817450 cites W2133531206 @default.
• W2894817450 cites W2134868034 @default.
• W2894817450 cites W2144625636 @default.
• W2894817450 cites W2148534890 @default.
• W2894817450 cites W2151488185 @default.
• W2894817450 cites W2152334952 @default.
• W2894817450 cites W2157823046 @default.
• W2894817450 cites W2193810110 @default.
• W2894817450 cites W2333563683 @default.
• W2894817450 cites W2397377428 @default.
• W2894817450 cites W2427727046 @default.
• W2894817450 cites W2465838633 @default.
• W2894817450 cites W2515716590 @default.
• W2894817450 cites W2536634227 @default.
• W2894817450 cites W2606977148 @default.
• W2894817450 cites W2607031352 @default.
• W2894817450 cites W2617848354 @default.
• W2894817450 cites W2753845492 @default.
• W2894817450 doi "https://doi.org/10.1159/000493951" @default.
• W2894817450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30293075" @default.
• W2894817450 hasPublicationYear "2018" @default.
• W2894817450 type Work @default.
• W2894817450 sameAs 2894817450 @default.
• W2894817450 citedByCount "7" @default.
• W2894817450 countsByYear W28948174502019 @default.
• W2894817450 countsByYear W28948174502020 @default.
• W2894817450 countsByYear W28948174502021 @default.
• W2894817450 countsByYear W28948174502023 @default.
• W2894817450 crossrefType "journal-article" @default.
• W2894817450 hasAuthorship W2894817450A5014374711 @default.
• W2894817450 hasAuthorship W2894817450A5014687439 @default.
• W2894817450 hasAuthorship W2894817450A5025814758 @default.
• W2894817450 hasAuthorship W2894817450A5042133353 @default.
• W2894817450 hasAuthorship W2894817450A5062233182 @default.
• W2894817450 hasAuthorship W2894817450A5062553515 @default.
• W2894817450 hasAuthorship W2894817450A5063253432 @default.
• W2894817450 hasAuthorship W2894817450A5075136340 @default.
• W2894817450 hasAuthorship W2894817450A5085338227 @default.
• W2894817450 hasAuthorship W2894817450A5087611125 @default.
• W2894817450 hasAuthorship W2894817450A5087798680 @default.
• W2894817450 hasBestOaLocation W28948174501 @default.
• W2894817450 hasConcept C126322002 @default.
• W2894817450 hasConcept C143998085 @default.
• W2894817450 hasConcept C168563851 @default.
• W2894817450 hasConcept C207103383 @default.
• W2894817450 hasConcept C2776694085 @default.
• W2894817450 hasConcept C2780258809 @default.
• W2894817450 hasConcept C2780739268 @default.
• W2894817450 hasConcept C44249647 @default.
• W2894817450 hasConcept C71924100 @default.
• W2894817450 hasConceptScore W2894817450C126322002 @default.
• W2894817450 hasConceptScore W2894817450C143998085 @default.
• W2894817450 hasConceptScore W2894817450C168563851 @default.
• W2894817450 hasConceptScore W2894817450C207103383 @default.
• W2894817450 hasConceptScore W2894817450C2776694085 @default.
• W2894817450 hasConceptScore W2894817450C2780258809 @default.
• W2894817450 hasConceptScore W2894817450C2780739268 @default.
• W2894817450 hasConceptScore W2894817450C44249647 @default.
• W2894817450 hasConceptScore W2894817450C71924100 @default.
• W2894817450 hasIssue "1" @default.
• W2894817450 hasLocation W28948174501 @default.
• W2894817450 hasLocation W28948174502 @default.

• next